FDA Accepts Tab cel BLA Resubmission
FDA accepted Pierre Fabre’s Class 2 resubmission of the tabelecleucel biologics license application for EBV-positive post-transplant lymphoproliferative disease and assigned a 31 March 2027 PDUFA date. This is a meaningful update to Insilens coverage…
